Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

TX002100

Other · developed by Tectonic Operating Company

Phase 1 Most advanced trial
TECX Developer
1 Registered trials

What is TX002100?

TX002100 is a drug studied in hereditary hemorrhagic telangiectasia (HHT).

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Cardiovascular
Developer
Tectonic Operating Company, Inc. (TECX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07863609 Phase 1 Hereditary Hemorrhagic Telangiectasia (HHT) Not yet recruiting TECX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hereditary Hemorrhagic Telangiectasia (HHT)

More from Tectonic Operating Company

TX000045 Phase 2

Follow TECX, the company behind TX002100

See TECX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TECX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.